9 December 2010 - Serodus has entered into a license agreement with Roche for a selective serotonin-4 (5-HT4) antagonist for the potential treatment of heart failure (RO1160367). Under the Agreement, Serodus will receive the full preclinical and clinical documentation for RO1160637. In return, Roche will receive an upfront payment as well as be entitled to receive development, regulatory and commercial milestone payments. Roche is also eligible to receive royalties on sales of products commercialized under the license. Serodus has been granted the exclusive development, manufacturing and worldwide marketing and sale rights with the rights to sub-license.
In certain cases, Roche has a right to negotiate to regain the product rights... Serodus' Press Release -
